[Corrigendum] Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation

After the publication of the above paper, the authors noted that an incomplete version of the address was presented for the second author affiliation; essentially, 'School of Medicine' had been omitted from the address. Therefore, the author and affiliation details for this paper should have been presented as follows: Kou‑Gi Shyu1,2, Marappan Velusamy3, Chih‑Wei Hsia2, Chih‑Hao Yang2, Chih‑Hsuan Hsia2, Duen‑Suey Chou2, Thanasekaran Jayakumar2, Joen‑Rong Sheu2 And Jiun‑Yi Li2,4. 1Division of Cardiology, Shin Kong Wu Ho‑Su Memorial Hospital, Taipei 111; 2Graduate Institute of Medical Sciences and Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan, R.O.C.; 3Department of Chemistry, North Eastern Hill University, Shillong, Meghalaya 793022, India; 4Department of Cardiovascular Surgery, Mackay Memorial Hospital, and Mackay Medical College, Taipei 104, Taiwan, R.O.C. The authors regret that the error with the second author affiliation was not noticed prior to the publication of their paper, and apologize for any inconvenience caused. [the original article was published in International Journal of Molecular Medicine 41: 2589‑2600, 2018; DOI: 10.3892/ijmm.2018.3472].